NGAL is a new biomarker for the diagnosis of acute kidney insufficiency or according to the terminology accepted abroad, acute kidney injury (AKI). The main advantage of NGAL is the earliest increase in its concentration in the development of acute kidney insufficiency, especially when compared with other renal markers. At the same time, the increase in the level of NGAL is proportional to the severity of developing kidney injury. Thus, NGAL allows early diagnostics and stratification of risks in the development of acute renal injury and makes possible the timely application of preventive therapy. Early diagnosis of acute kidney insufficiency allows making clinical decisions in the shortest time before the onset of acute kidney insufficiency and making proactive measures to stop declining kidney function.